Martin Berman-Gorvine Articles

doctor checking measuring blood pressure on patient's hand

Apr 20, 2023 by Martin Berman-Gorvine

Is This MedTech Giant a No-Brainer Buy With Its Latest Advances?

Strong footprints in neuroscience and other major medical research areas give the company a broad basis for future growth.

Apr 20, 2023 by Martin Berman-Gorvine

Curaleaf Faces a Potentially Decisive Year. Will Big States Make a Difference?

Will investors see the company's breakthrough to profitability in 2023?

Apr 14, 2023 by Martin Berman-Gorvine

Here's Why Lawsuits Likely Won't Slow UnitedHealth Down

With net earnings of $20 billion last year and almost $70 billion in cash and cash equivalents, UnitedHealth seems well-positioned for further growth.

Apr 11, 2023 by Martin Berman-Gorvine

Can Axsome Hold Out Till Depression Drug Becomes a Blockbuster?

Has the company bitten off more than it can chew in R&D, or will its depression drug launch it into the stratosphere?

diabetes CGM continuous glucose monitor blood

Apr 5, 2023 by Martin Berman-Gorvine

Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market

Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years.

Mar 31, 2023 by Martin Berman-Gorvine

Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?

EDIT-301 had positive clinical results in treating sickle cell disease, but the potential payoff is still years in the future.

cancerous cell cancer danger sick infected

Mar 27, 2023 by Martin Berman-Gorvine

Roche's Slow Growth Shouldn't Drive Investors Away

New treatments for various cancers, eye diseases, and more may bring in future revenues.

Mar 22, 2023 by Martin Berman-Gorvine

Is Universal Health Services Stock a Bargain Following Hospital Closure?

Behavioral health offerings could be the answer for Universal Health Services' future growth.

brain scan doctor x-ray CT technician nurse2

Mar 17, 2023 by Martin Berman-Gorvine

Wall Street Is Bullish on GE HealthCare as It Invests in AI

The stand-alone company that spun off from GE in January is off to a good start.

Mar 13, 2023 by Martin Berman-Gorvine

Betting Big on Florida, Cannabis Retailer Green Thumb Faces Price Squeeze

Is Florida sunshine the cure for what ails Green Thumb?

Mar 7, 2023 by Martin Berman-Gorvine

1 Undervalued Healthcare Stock That's Worth a Second Look

Elevance touts a growing customer base.

Mar 3, 2023 by Martin Berman-Gorvine

Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval

The French drug company got the nod for a hemophilia treatment.

Feb 28, 2023 by Martin Berman-Gorvine

Royal Philips Dragged Down by Ever-Expanding Ventilator Recall

Cancer-causing toxic particles are a significant problem for the Netherlands-based firm.

a scientist uses a pipette to work with medical samples.

Feb 23, 2023 by Martin Berman-Gorvine

Don't Get Panicked Into Selling Off Merck Shares

The current drop in 2023 sales likely won't matter in the long term.

Coronavirus vaccine vials in hospital with money

Feb 22, 2023 by Martin Berman-Gorvine

Pharma Giant Pfizer Looks Strong for Investors, Despite COVID Sales Drop

The company is doubling down on its vaccine success.

adult and young child wash dishes in the kitchen sink

Jun 28, 2021 by Martin Berman-Gorvine

Can Clorox Transform Its Pandemic Boost into Permanent Gains?

Clorox may not be nimble enough to take advantage of the demand opportunity that came its way during the pandemic. But there's more to like about the business.

Martin Berman-Gorvine

Recent Articles by Martin Berman-Gorvine